• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Science and Business Do Mix: The Rimon Therapeutics Story
 

Science and Business Do Mix: The Rimon Therapeutics Story

on

  • 369 views

Speaker: Dr. Michael May, CEO of Rimon Therapeutics ...

Speaker: Dr. Michael May, CEO of Rimon Therapeutics
Michael May is the CEO of Rimon Therapeutics, a company he founded to commercialize his thesis work at U of T. In this presentation, Michael discusses what it is like making the transition from the lab to the boardroom.
More information: http://www.marsdd.com/Events/Event-Calendar/Ent101/2007/Science-and-business-do-mix-20071128.html

Statistics

Views

Total Views
369
Views on SlideShare
369
Embed Views
0

Actions

Likes
1
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Science and Business Do Mix: The Rimon Therapeutics Story Science and Business Do Mix: The Rimon Therapeutics Story Presentation Transcript

    • Michael H. May PhDMichael H. May PhD President and Co-FounderPresident and Co-Founder Science and Business Do MixScience and Business Do Mix Entrepreneurship 101, MaRS, Nov 28Entrepreneurship 101, MaRS, Nov 28thth , 2007, 2007
    • “The beginning of awe is wonder and the beginning of wisdom is awe” Rabbi Abraham Joshua Heschel Wonder Awe Wisdom Why a Scientist/EntrepreneurWhy a Scientist/Entrepreneur
    • Modest beginnings…Modest beginnings… Key Messages:Key Messages:  Entrepreneurial interest was sparked by awe of science  I did my PhD to start a company  Rimon started from a single experimental observation The Theramer™ Company
    • Modest beginnings…Modest beginnings… Key Messages:Key Messages:  Entrepreneurial interest was sparked by awe of science  I did my PhD to start a company  Rimon started from a single experimental observation The Theramer™ Company
    • MotivationMotivation After 4 weeks of MI-SorbAfter 4 weeks of MI-Sorb™™ treatmenttreatment Prior to treatment with MI-SorbPrior to treatment with MI-Sorb™™ DressingDressing “I have been doing research for 30 years and this is the first time that something I have worked on is being tested on humans” Professor. Michael Sefton, Co-Founder - after a long day with the Board on clinical trial design and patient recruitment The Theramer™ Company
    •  Spun-out of the University of Toronto in 2000  5 core technologies  Potential partners engaged for several product concepts  11 patents issued or pending, own rights to all IP  Extensive R&D network around local biomaterials centre of excellence Corporate BackgroundCorporate Background The Theramer™ Company
    • The TheramerThe Theramer™ Company™ Company Theramers™ are medical polymers that have inherent biological activity without the incorporation of pharmaceuticals or cells. Core TechnologiesCore Technologies::  MI - MMP inhibition  AM - antimicrobial activity  Angiogenic – new blood vessel formation  ThermaGel™ - temperature responsive Competitive Advantages:Competitive Advantages:  Regulated as devices not drugs  Versatile chemistry – broad application  Non-biologic, non-eluting  Localized activity, no systemic consequences  Easy to manufacture The Theramer™ Company
    • Drug-likeDrug-like Activity/MarginsActivity/Margins DeviceDevice TimelinesTimelines Versatility ofVersatility of PolymersPolymers Unique Value PropositionUnique Value Proposition The Theramer™ Company
    • Corporate Feasibility Licensing Revenue Stent Restenosis Catheter Infection Research Partners Joint Disease New Polymer Design Product Focus Pre-Clinical Validation Clinical Validation Eye Disorders Chronic Skin Wounds Rimon In-house Theramer Product #2 H22007 Strategic Partnership Product PipelineProduct Pipeline Market sizes: all large markets with substantial segmentsMarket sizes: all large markets with substantial segments The Theramer™ Company
    • Key Features:Key Features:  Inhibits MMPs  Easy to apply and remove  Absorbent  Non-adherent  Non-toxic, non-sensitizing, non- irritating, non-hemolytic MI-SorbMI-Sorb™™ DressingDressing The Theramer™ Company
    • Overall Objective:Overall Objective: Demonstrate MI-Sorb™ Dressing safety and efficacy RIM001 Clinical TrialRIM001 Clinical Trial A B C D RIM001 is a randomized, multi-centre pilot studyRIM001 is a randomized, multi-centre pilot study Outcomes:Outcomes:  Recorded Adverse Events  Wound MMP Activity  Change in wound bed appearance and wound size Wound Types:Wound Types: A. Venous Stasis Ulcers (VSU) B. Diabetic Ulcers (DU) C. Pressure Sores (PS) D. Miscellaneous Wounds (Misc) The Theramer™ Company
    • Grouped MMP analysis:Grouped MMP analysis:  Significant treatment effect compared to baseline (from week 4 onwards) MI-SorbMI-Sorb™™ EfficacyEfficacy Pooling by treatment regime:Pooling by treatment regime:  Significant reduction in active MMP fraction with MI-Sorb™ vs. control treatment The Theramer™ Company 0 5 10 15 20 25 30 MI-SorbTM Treatment Control Treatment Increasing MMP Activity MI-SorbTM treatment lowers wound MMP activity by 77% compared to control treatment*. * A commercially available foam dressing 0 5 10 15 20 25 30 MI-SorbTM Treatment Control Treatment Increasing MMP Activity MI-SorbTM treatment lowers wound MMP activity by 77% compared to control treatment*. * A commercially available foam dressing Aim to be “Best in Class”Aim to be “Best in Class” in a new approach toin a new approach to move chronic woundsmove chronic wounds towards a healingtowards a healing pathwaypathway
    • MI-SorbMI-Sorb™™ EfficacyEfficacy Baseline MMP-2 Masson’s MMP-2 Masson’s After 4 weeks of MI-SorbTM Treatment Migrating, less friable wound edges; pink and firm granulation tissue Reduced MMP-2 staining (brown) Organised collagen (blue); little fibrin (red); reduced cellularity
    • MI-SorbMI-Sorb™™ CommercializationCommercialization Next Steps:Next Steps:  Leverage data into additional applications and next round of financing  ISO 13485 certification  CE Mark, 510k  Commercial manufacturing  Marketing and distribution The Theramer™ Company
    • Some Important Success FactorsSome Important Success Factors The Theramer™ Company
    • Some Important Success FactorsSome Important Success Factors Key Corporate Values:Key Corporate Values:  Recognize Opportunity  Keep it Simple  Be Persistent  Focus on Execution The Theramer™ Company
    • Opportunity in the UnexpectedOpportunity in the Unexpected The Theramer™ Company
    • Opportunity in the UnexpectedOpportunity in the Unexpected Key Messages:Key Messages:  Rimon was founded on a serendipitous observation  Many of our most valuable results came from unplanned observations  Innovation = something unexpected with value The Theramer™ Company
    • Simple is BestSimple is Best The Theramer™ Company
    • Simple is BestSimple is Best Key Messages:Key Messages:  Simple is easier to defend and validate  Simple is time efficient  Simple is much easier to sell  But, it is hard to be simple The Theramer™ Company
    • There is Always a WayThere is Always a Way Key Messages:Key Messages:  Survival is an achievement  We have been most innovative when “our backs were to the wall”  Persistence and endurance build credibility The Theramer™ Company
    • VSU- ControlVSU- Control 0 200 400 600 800 1000 1200 1400 1600 2 3 4 5 6 Study Week Normalized MMP Units VSU- MI-SorbVSU- MI-Sorb™™ MI-SorbMI-Sorb™™ EfficacyEfficacy Patient-Based MMP AnalysisPatient-Based MMP Analysis::  Examines MI-Sorb™ efficacy on a wound-by-wound basis Decreased MMP activity relative to underlying inflammation Increased MMP activity relative to underlying inflammation MI-Sorb™ reduces the activeMI-Sorb™ reduces the active MMP fraction relative toMMP fraction relative to underlying inflammationunderlying inflammation > The Theramer™ Company
    • Execute, Execute, ExecuteExecute, Execute, Execute The Theramer™ Company
    • Execute, Execute, ExecuteExecute, Execute, Execute Key Messages:Key Messages:  Under promise and over achieve  Create back-up plans for what is out of your control  Achievements bring validation and credibility The Theramer™ Company
    • $ time High Risk of Failure (“Pit of Hell”) 1 in 3000 Execution = Risk MitigationExecution = Risk Mitigation Value = Next FinancingValue = Next Financing Risk Mitigation =Value CreationRisk Mitigation =Value Creation F1 F2 F3 Profile of an R&D Start-upProfile of an R&D Start-up The Theramer™ Company
    •  Market Size - $1 billion  Growth – 5 % annually  Licensing partner’s share – 33 %  Adoption rate – 75 %  License fee – 20 %  Number of key technologies – 2  Cost to market - $4 million over 3 years  Timeline – 10 years  Net Present Value (NPV) - $30 million The Value of an IdeaThe Value of an Idea The Theramer™ Company
    • Corporate Feasibility Licensing Revenue Research Partners Polymer Design Product Focus Pre-Clinical Validation Clinical Validation Rimon In-house Strategic Partnership Execution Mitigates RiskExecution Mitigates Risk p< 80% p< 80% p< 10% p< 33% p< 10% IP Protection Freedom to Operate Scale-up Manufacturing Regulatory Re-imbursement POC Material Development POA Material Development POP Material Development p< 25% p< 50% p< 80% p< 60% p< 33% The Theramer™ Company Overall probability ofOverall probability of success is very low!success is very low!
    •  NPV of idea discounted for risk (80%) - < $200,000  NPV is negative with less than 1 year delay in plan  NPV is negative if costs underestimated by < 10% Mitigating Risk Enhances ValueMitigating Risk Enhances Value $ time The Theramer™ Company
    • OCE MaRS Two key features of aTwo key features of a small-world network:small-world network: • Strong close links built on trust (e.g., research collaborators, service providers) • A few links that are connected widely (e.g., directors, world-renowned scientists) Me, Myself and My NetworkMe, Myself and My Network The Theramer™ Company
    • • Overlap technical networkOverlap technical network • basic science into ideas • ideas into technologies • technologies into products • products into a company • Expand networkExpand network • shareholder, customers • Strengthen networkStrengthen network • Flow of information, resources, $, products Build network towards a “tipping point”Build network towards a “tipping point” High Tech EntrepreneurshipHigh Tech Entrepreneurship The Theramer™ Company
    • • Take care of the hard science first • Championing a start-up is a full-time job • Early-stage start-ups are an intense learning environment • Focus first on the people that will help build and strengthen your network (e.g., lawyers, accountants) • Practise communicating/negotiating • Develop a thick skin • Be bold – graduate student entrepreneurs are an untapped, coachable source of entrepreneurs • Just get going! Final ThoughtsFinal Thoughts The Theramer™ Company
    • “No pessimist ever discovered the secret of the stars or sailed an uncharted land, or opened a new doorway for the human spirit...Life is either a daring adventure or nothing” Helen Keller Thank You!Thank You! The Theramer™ Company